Black Diamond Therapeutics
BDTX
59 hedge funds and large institutions have $37.8M invested in Black Diamond Therapeutics in 2022 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 8 increasing their positions, 26 reducing their positions, and 19 closing their positions.
4% more capital invested
Capital invested by funds: $36.3M → $37.8M (+$1.45M)
1.26% less ownership
Funds ownership: 59.15% → 57.89% (-1.3%)
14% less funds holding
Funds holding: 69 → 59 (-10)
35% less call options, than puts
Call options by funds: $50K | Put options by funds: $77K
53% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 19
69% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 26
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$1.32M |
| 2 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$1.23M |
| 3 |
EC
EcoR1 Capital
San Francisco,
California
|
+$508K |
| 4 |
Millennium Management
New York
|
+$320K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$96.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KPF
K2 Principal Fund
Toronto,
Ontario, Canada
|
-$1.57M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$544K |
| 3 |
BlackRock
New York
|
-$486K |
| 4 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$389K |
| 5 |
Morgan Stanley
New York
|
-$357K |
BDTX Hedge Fund Activity: Q4 2022 in Review
59 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in Black Diamond Therapeutics (BDTX) for Q4 2022, worth a combined $37.8M — up 4% from $36.3M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of BDTX and 9 opened new positions — a net loss of 10 holders — while 26 trimmed existing stakes and 8 added.
The largest buyer was Citadel Advisors, adding an estimated $1.32M. The largest seller was K2 Principal Fund, cutting an estimated $1.57M.
- 59 institutional investors held Black Diamond Therapeutics (BDTX) as of Q4 2022, down from 69 in Q3 2022.
- Funds reported $37.8M of Black Diamond Therapeutics stock for Q4 2022, up 4% quarter-over-quarter.
- 9 funds opened new Black Diamond Therapeutics positions in Q4 2022 and 19 closed out, a net change of -10 holders.
- The largest Black Diamond Therapeutics buyer in Q4 2022 was Citadel Advisors, an estimated $1.32M added.
- The largest Black Diamond Therapeutics seller in Q4 2022 was K2 Principal Fund, an estimated $1.57M sold.
Based on aggregated 13F filings for Q4 2022.